We are a global company that is proud of our strong R&D capabilities in Japan. We are already fully commercially integrated in Europe.

Shionogi Global

Founded in Osaka in 1878, we are a leading Japanese pharmaceutical company. We have a global footprint across Asia, North America and Europe and generated $3.1 billion in revenue in 2022. With over 30 ongoing development programs and $470 million invested in R&D, we continue to focus on shaping the future of healthcare.

Shionogi global. 1878 - founded in Osaka, Japan. $3.1 billion in FY22 revenue. 3 Continents direct presence, Asia, North America, Europe. >30 programs ongoing. $470 million in R&D investment

Shionogi Europe

Here at Shionogi Europe, we have five fully operational affiliate offices in the UK, France, Italy, Spain and Germany, alongside our Headquarters in the Netherlands. We have over 300 employees and additional geographic reach ensuring strong coverage of the biggest markets in Europe.


We have significant expertise in infectious diseases and other areas of unmet clinical needs within our Hospital Specialty Business, and a strong track record in other therapy areas affecting quality of life, particularly Women’s Health.

Shionogi Europe. 12 geographies in Europe - commercial sales in Italy, Germany, UK, France, Spain, Sweden, Austria, Switzerland, Netherlands, Denmark, Norway & Finland. >300 Employees in Europe.

Hospital speciality pharmaceuticals

Infectious disease, ICU, Gram negative bacteria

Development of innovative products in-house to address several indications and therapeutic areas with high unmet medical needs, including GN infections and CLD-Thrombocytopenia.

Other therapeutic areas

Woman's health, Pain

Beyond our work in infectious diseases, we strive to find solutions to other unmet clinical needs and wider health issues facing society. We have a track record in the therapeutic areas of Women’s Health and Pain.

NP-EU-NP-0283 | June 2024